To investigate the incidence of SARS-CoV-2 infections after vaccination, to monitor the development of SARS-CoV-2 antibody levels after vaccination and to compare this in relation to both previous health \& disease, previous antibody responses and in relation to future disease occurring after vaccination.
The purpose of the study is to analyze the effect of and possible side effects of SARS-CoV2 vaccinations in the cohort study where data on sick leave, SARS-Cov2 infections and SARS-CoV2 antibody levels are well documented even before vaccination. The main outcome measures are the presence of SARS-CoV-2 (ongoing infection) and the presence of antibodies to SARS-CoV-2. For the vaccination effect, the factors that are primarily associated with protection against infection are analyzed, such as age, sex, workplace, antibody response to SARS-CoV-2 and vaccination date. The analyzes are planned to be performed with multivariate logistic regression with Relative Risk as the outcome measure. Data from the analysis of virus antibodies are planned to be performed divided into whether low, medium or high levels of antibodies occur, with the same analysis for possible association with the factors listed above.
Study Type
OBSERVATIONAL
Enrollment
10,000
Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
Karolinska University Hospital
Stockholm, Sweden
SARS-CoV-2 infection
Characterized by whether they are asymptomatic infections or sick leave-requiring infections.
Time frame: 24 months post primary vaccination
SARS-CoV-2 antibody induction
Antibodies will be characterized in terms of antibody levels, which SARS-CoV-2 antigen to which the response is directed and whether the antibodies are protective or not.
Time frame: 24 months post primary vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.